Overview
Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis
Status:
Completed
Completed
Trial end date:
2020-02-01
2020-02-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to compare the safety and efficacy of masitinib 6 mg/kg/day versus placebo in the treatment of patients with primary progressive multiple sclerosis or relapse-free secondary progressive multiple sclerosis.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
AB Science
Criteria
Main inclusion criteria:- Patient suffering from either primary progressive or secondary progressive multiple
sclerosis without relapse within 2 years before inclusion according to the revised
McDonald's criteria.
Main exclusion criteria:
- Patient suffering from a disease other than MS that would better explain the patient's
neurological clinical signs and symptoms and/or MRI lesions